MBHB Snippets: Review of Developments in Intellectual Property Law - Volume 10, Issue 2 - Spring 2012

In This Issue:

Enter at Your Own Risk: FDA Draft Guidance Highlights the Uncertainty in the Abbreviated Biosimilar Approval Pathway; McDonnell Boehnen Hulbert & Berghoff LLP to Exhibit at 2012 BIO International Convention in Boston; The Murky Morass of Section 101; Exploring the Dichotomy Between Patent and Antitrust Law; and The Coach Services, Inc. v. Triumph Learning, LLC Case: What it Means for a Trademark to Be “Famous” for Trademark Dilution Purposes.

Excerpt from Enter at Your Own Risk: FDA Draft Guidance Highlights the Uncertainty in the Abbreviated Biosimilar Approval Pathway

By 2015, sales of biosimilars in the United States are expected to reach as high as $2.6 billion. Recognizing this market opportunity, biotech companies of all sizes are devoting significant resources to developing these biologic products, which are novel yet dependent on currently approved biologic drug products (at least in part). Following the passage of the Biologics Price Competition and Innovation Act (BPCIA) on March 23, 2010, an entity seeking to bring a biosimilar product to market now has two pathways to consider for securing Food and Drug Administration (FDA) approval. One pathway allows the biosimilar applicant (BA) to seek FDA approval of the product as a new biologic by filing a biologic license application (BLA) under § 351(a) of the Public Health Service Act (PHSA). Alternatively, the BA can follow the newly enacted abbreviated pathway under PHSA § 351(k), which created a new approval pathway for biologics that the FDA determines are “biosimilar” to a BLA-approved reference product (RP). This second option has been available since the passage of the BPCIA on March 23, 2010, yet the FDA still awaits the filing of the first § 351(k) application (referred to as abbreviated biologic license application – “ABLA”).

Please see full issue below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, Antitrust & Trade Regulation Updates, Communications & Media Updates, Intellectual Property Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

CONNECT

At McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB"), we provide creative, pragmatic business... View Profile »


Follow McDonnell Boehnen Hulbert & Berghoff LLP:

Reporters on Deadline